• 1
    Reid IR 1999 Pharmacological management of osteoporosis in postmenopausal women: A comparative review. Drugs Aging 15:349363.
  • 2
    Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R 1993 Anabolic actions of parathyroid hormone on bone. Endocrinol Rev 14:690709.
  • 3
    Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550555.
  • 4
    Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R 2001 Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 16:925931.
  • 5
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:14341441.
  • 6
    Turner CH, Wang T, Hirano T 1999 In primates, treatment with PTH (1–34), teriparatide, increases bone strength at trabecular bone sites without compromising the strength of cortical bone. J Bone Miner Res 14:S1;S414.
  • 7
    Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16:18461853.
  • 8
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barret-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk for fractures in women with low BMD but without vertebral fractures. JAMA 280:20772082.
  • 9
    McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333340.
  • 10
    Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore M, Ma L, Nold JB 2002 Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol 30:312321.
  • 11
    Tashjian AH Jr, Chabner BA 2002 Commentary on clinical safety of recombinant human parathyroid hormone (1–34) in the treatment of osteoporosis in postmenopausal women and in men. J Bone Miner Res 17:11511161.
  • 12
    Genant HK, Wu CY, van Kuijk C, Nevitt MC 1993 Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:11371148.
  • 13
    Lu Y, Ye K, Mathur AK, Hui S, Fuerst TP, Genant HK 1997 Comparative calibration without a gold standard. Stat Med 16:18891905.
  • 14
    Lu Y, Mathur AK, Blunt BA, Gluer CC, Will AS, Fuerst TP, Jergas MD, Andriano Cummings SR, Genant HK 1996 Dual X-ray absorptiometry quality control: Comparison of visual examination and process-control charts. J Bone Miner Res 11:626637.
  • 15
    Gallagher JC 1999 Moderation of the daily dose of HRT: Prevention of osteoporosis. Maturitas 33:S57S63.
  • 16
    Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase Osteoporosis Treatment Study Group. N Engl J Med 333:14371443.